AU506385B2 - Hepatitis b virus; isolation for vaccines - Google Patents

Hepatitis b virus; isolation for vaccines

Info

Publication number
AU506385B2
AU506385B2 AU23313/77A AU2331377A AU506385B2 AU 506385 B2 AU506385 B2 AU 506385B2 AU 23313/77 A AU23313/77 A AU 23313/77A AU 2331377 A AU2331377 A AU 2331377A AU 506385 B2 AU506385 B2 AU 506385B2
Authority
AU
Australia
Prior art keywords
vaccines
hepatitis
virus
isolation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
AU23313/77A
Other languages
English (en)
Other versions
AU2331377A (en
Inventor
LO. Einarsson G. M. and Kaplan L. P Andersson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Phadia AB
Original Assignee
Kabi AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kabi AB filed Critical Kabi AB
Publication of AU2331377A publication Critical patent/AU2331377A/en
Application granted granted Critical
Publication of AU506385B2 publication Critical patent/AU506385B2/en
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU23313/77A 1976-03-18 1977-03-16 Hepatitis b virus; isolation for vaccines Expired AU506385B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SESE7603386 1976-03-18
SE7603386A SE420977B (sv) 1976-03-18 1976-03-18 Forfarande for rening och isolering av hepatitvirus for vaccinframstellning

Publications (2)

Publication Number Publication Date
AU2331377A AU2331377A (en) 1978-09-21
AU506385B2 true AU506385B2 (en) 1979-12-20

Family

ID=20327330

Family Applications (1)

Application Number Title Priority Date Filing Date
AU23313/77A Expired AU506385B2 (en) 1976-03-18 1977-03-16 Hepatitis b virus; isolation for vaccines

Country Status (10)

Country Link
US (1) US4138287A (US06724976-20040420-M00002.png)
JP (1) JPS52114018A (US06724976-20040420-M00002.png)
AU (1) AU506385B2 (US06724976-20040420-M00002.png)
BE (1) BE852416A (US06724976-20040420-M00002.png)
CA (1) CA1073815A (US06724976-20040420-M00002.png)
DE (1) DE2711773A1 (US06724976-20040420-M00002.png)
FR (1) FR2344629A1 (US06724976-20040420-M00002.png)
GB (1) GB1511997A (US06724976-20040420-M00002.png)
NL (1) NL7702784A (US06724976-20040420-M00002.png)
SE (1) SE420977B (US06724976-20040420-M00002.png)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4181713A (en) * 1978-10-30 1980-01-01 Merck & Co., Inc. Isolation of HBs Ag
US6297355B1 (en) 1978-12-22 2001-10-02 Biogen, Inc. Polypeptides displaying HBV antigenicity or hbv antigen specificity
US4242324A (en) * 1979-04-04 1980-12-30 Merck & Co., Inc. Hepatitis B antigen
US4395395A (en) * 1979-05-21 1983-07-26 The United States Of America As Represented By The Department Of Health And Human Services Detection of non-A, non-B hepatitis associated antigen
PL133476B1 (en) * 1981-06-10 1985-06-29 Akad Medyczna Method of obtaining pure antigen hba from human serum
AU8746582A (en) * 1981-09-02 1983-03-10 Biogen N.V. Hepatitis b virus e type antigen
US7767449B1 (en) * 1981-12-24 2010-08-03 Health Research Incorporated Methods using modified vaccinia virus
US4603112A (en) * 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
US4511473A (en) * 1982-02-09 1985-04-16 Amf Incorporated Fibrous media containing millimicron-sized particulates
US4515714A (en) * 1983-03-09 1985-05-07 Juridicial Foundation, The Chemo-Semo-Sero-Therapeutic Research Institute Method for purification of hepatitis B virus surface antigen
JPS59164727A (ja) * 1983-03-09 1984-09-17 Chemo Sero Therapeut Res Inst Ｂ型肝炎ウイルス表面抗原の精製方法
JPS59219239A (ja) * 1983-05-28 1984-12-10 Chemo Sero Therapeut Res Inst Ｂ型肝炎ウイルス表面抗原の精製方法
AU571078B2 (en) * 1984-04-14 1988-03-31 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Purification of filamentous hemagglutinin
JPS6147185A (ja) * 1984-08-09 1986-03-07 Chemo Sero Therapeut Res Inst 日本脳炎ウイルスの精製方法
JPS6147186A (ja) * 1984-08-09 1986-03-07 Chemo Sero Therapeut Res Inst インフルエンザウイルスの精製方法
JPS6147187A (ja) * 1984-08-10 1986-03-07 Chemo Sero Therapeut Res Inst 狂犬病ウイルスの精製方法
JPS6153226A (ja) * 1984-08-24 1986-03-17 Chemo Sero Therapeut Res Inst 単純ヘルペスサブユニツトワクチンの精製方法
JPS61103895A (ja) * 1984-10-26 1986-05-22 Green Cross Corp:The ＨＢｓＡｇの精製方法
SE503844C2 (sv) 1989-02-09 1996-09-16 Pharmacia Ab Förfarande för rening av streptokinaser
US5447859A (en) * 1993-07-16 1995-09-05 Viagene Method for the purification or removal of retroviruses using sulfated cellulose
JP3615785B2 (ja) * 1994-04-28 2005-02-02 テルモ株式会社 Ｈｉｖ及びその関連物質除去材料
GB9804632D0 (en) * 1998-03-05 1998-04-29 Cantab Pharma Res Virus preparations and methods
US6221855B1 (en) * 1999-03-11 2001-04-24 Wake Forest University Regulation of nucleic acid expression by heparan sulfate and biological equivalents thereof
DE602004028736D1 (de) * 2003-06-20 2010-09-30 Microbix Biosystems Inc Verbesserungen bei der virusproduktion
EP3290513B1 (en) * 2004-06-01 2022-09-07 Genzyme Corporation Compositions and methods to prevent aav vector aggregation
EP2066418A4 (en) * 2006-09-29 2011-12-28 Ge Healthcare Bio Sciences Ab SEPARATION MATRIX FOR VIRAL PURIFICATION
CN114210310B (zh) * 2021-12-06 2023-09-29 武汉瑞法医疗器械有限公司 乙型肝炎病毒和HBsAg免疫吸附材料的制备方法及应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3636191A (en) * 1969-10-08 1972-01-18 Cancer Res Inst Vaccine against viral hepatitis and process
US3925152A (en) * 1971-06-18 1975-12-09 Exploaterings Ab Tbf Virus separation
US3896218A (en) * 1972-07-13 1975-07-22 Research Corp Radiommunoassay determining the hepatitis associated antigen content of blood
US3994870A (en) * 1974-01-31 1976-11-30 The Community Blood Council Of Greater New York, Inc. Purification of hepatitis B surface antigen
US3976767A (en) * 1975-04-14 1976-08-24 The New York Blood Center Purification of hepatitis B surface antigen by chromatography on agarose containing aminoalkyl residues
IL49752A (en) * 1975-07-09 1979-07-25 Kabi Ab Compositions having affinity for hepatitis virus and method for hepatitis virus removal or concentration

Also Published As

Publication number Publication date
NL7702784A (nl) 1977-09-20
BE852416A (fr) 1977-07-01
JPS52114018A (en) 1977-09-24
DE2711773A1 (de) 1977-09-22
FR2344629A1 (fr) 1977-10-14
US4138287A (en) 1979-02-06
GB1511997A (en) 1978-05-24
FR2344629B1 (US06724976-20040420-M00002.png) 1983-07-18
SE7603386L (sv) 1977-09-19
SE420977B (sv) 1981-11-16
AU2331377A (en) 1978-09-21
CA1073815A (en) 1980-03-18

Similar Documents

Publication Publication Date Title
AU506385B2 (en) Hepatitis b virus; isolation for vaccines
AU510068B2 (en) Hepatitis virus removal
AU528776B2 (en) Pasteurellosis vaccines
AU510809B2 (en) Method for combating virus infections
NO790195L (no) Fremgangsmaate for fremstilling av interferon
NO152774C (no) Fremgangsmaate for fremstilling av et antigenpreparat med virkning mot dental-karies.
AU8746582A (en) Hepatitis b virus e type antigen
AU504454B2 (en) Hepatitis b antigen and vaccine
GB2009786A (en) Virus propagation
AU529128B2 (en) Pneumonococcal vaccine
ZA774733B (en) Vaccines
AU4454679A (en) Antigen derivatives
AU2454077A (en) Equine rhinopneumonitis virus
AU505999B2 (en) Hepatitis vaccine
AU501313B2 (en) Thermal powerplant
GB2001851B (en) Vaccine preparations
DK345180A (da) Boerstestoevsuger
ZA803845B (en) Polyvalent virus vaccines
IL58947A0 (en) Vaccines against viral illnesses
AU506141B2 (en) Virus insecticide composition
GB2048066B (en) Rabies vaccine
AU513734B2 (en) Live influenza virus vaccine
JPS52134019A (en) Micoplasma galicepticum infection vaccine
GB2029219B (en) Pasteurellosis vaccines
AU500651B2 (en) Feline viral phionotracheitus vaccine